I bought a few shares when it fell to $29. I don't think the IPO lockout expiration will be that bad because it's selling far under the IPO price. If it does fall I'll buy more.
Boiler Room: The Official Stock Market Discussion
ahomeplateslugger
Superstar
i think we'll see something like a 12% drop. i don't think employees are going to wait until the stock recovers to or above its ipo price as it was already overvalued out the gate, plus who knows how long that's gonne be. with softbank being on edge since wework fukked their money up and uber's work culture going downhill i think workers are trying to cash out and leave. uber paid out stock compensation in Q2 and that caused a 9% drop. i'm just hoping for the best as my strike price is $30 and expiration is 11/8.
Just bought the Crypto this morning after the $10 became available.
I'll see if I get the bonus $25.
Did you ever get your bonus for me signing up?
Do you have the original link to this? Doing digging this weekend
Futuristic Eskimo
All Star
Interested as well. I've been reading more about this recently and would appreciate any information.
@Domingo Halliburton
Domingo Halliburton
Handmade in USA
It appears his blog at martinshkreli.com is no longer hosted by GoDaddy. I believe this is related to the trouble he has gotten into at jail. Apparently he was still trying to run his pharma company behind bars with a contraband cell phone. He may be in solitary confinement now. I cant find a direct link to it anymore only articles mentioning it.
Futuristic Eskimo
All Star
Shame. Stock tips from men in jail for securities fraud are usually on point
SAN DIEGO, Nov. 1, 2019 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced today new data demonstrating that suppression of NR2F6 using patent-pending compounds developed by the Company results in selective inhibition of new blood vessels under conditions associated with cancer and wet macular degeneration. The data, which was obtained using human umbilical vein endothelial cells (HUVEC), indicates that NR2F6 may have a larger biological role than originally suspected.' data-reactid="12">SAN DIEGO, Nov. 1, 2019 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced today new data demonstrating that suppression of NR2F6 using patent-pending compounds developed by the Company results in selective inhibition of new blood vessels under conditions associated with cancer and wet macular degeneration. The data, which was obtained using human umbilical vein endothelial cells (HUVEC), indicates that NR2F6 may have a larger biological role than originally suspected.
Regen BioPharma, Inc. has been utilizing NR2F6 as a target for immune modulation and cancer stem cells. To the Company's knowledge, this is the first indication to date that NR2F6 is involved in the formation of new blood vessels.
Thomas Ichim, PhD, co-inventor of the patent and consultant to the Company. "In our experiments, we observed that inhibition of NR2F6 selectively blocked multiplication of blood vessel cells that were stimulated with Vascular Endothelial Growth Factor (VEGF). Since VEGF is associated with disease conditions, it is possible that our approach possesses some degree of specificity in blocking pathological but not healthy formation of new blood vessels. New blood vessels suggests that this approach may not suppress healthy blood vessels which are primarily formed independently of VEGF."' data-reactid="14">"New blood vessels are typically not formed in an adult except in conditions such as cancer (in which the tumor cells require a new blood supply) or in wet macular degeneration; a condition in which new blood vessels result in impairment of vision," said Thomas Ichim, PhD, co-inventor of the patent and consultant to the Company. "In our experiments, we observed that inhibition of NR2F6 selectively blocked multiplication of blood vessel cells that were stimulated with Vascular Endothelial Growth Factor (VEGF). Since VEGF is associated with disease conditions, it is possible that our approach possesses some degree of specificity in blocking pathological but not healthy formation of new blood vessels. New blood vessels suggests that this approach may not suppress healthy blood vessels which are primarily formed independently of VEGF."
$2.8 Billion in 20181) for cancer and Lucentis (Sales $1.9 Billion in 20182).' data-reactid="15">Drugs which target VEGF as a means of suppressing pathological blood vessel formation include Avastin (Sales $2.8 Billion in 20181) for cancer and Lucentis (Sales $1.9 Billion in 20182).
David Koos. "We believe this coupled with our current small molecule therapies as a quality additional approach to treating cancer."" data-reactid="16">"What this data demonstrates is a potential mechanism to kill cancer cells without the toxicity associated with conventional treatments," noted the Company's Chairman & CEO David Koos. "We believe this coupled with our current small molecule therapies as a quality additional approach to treating cancer."
Yahoo is now part of Verizon Media
Its cheap af, so I have over a million shares here. When AMRN gets over $20, I prolly stop buying and start building up RGBP again. They are still in Phase 1/2, so its def a long term play, but I don't mind the risk. They recently announced some shyt reducing, or preventing RI.
Heres the other link:
Regen BioPharma Successfully Treats Rheumatoid Arthritis Using Cannabidiol (CBD) Based Immune Modulatory Treatments
Im heavy AF in Biotech right now. Ill take a look into those companies he listed for sure.
Domingo Halliburton
Handmade in USA
Speaking of Shkreli here's a link to a bunch of youtube videos he's done. These are basically university level courses he's provided on investing and finance. He also delves into other subjects like chemistry and how to evaluate clinical trials. The dude is wicked smart.
Heres the archive:
Index of /archive/
Heres the archive:
Index of /archive/
I was up for hours watchin this last night. This is REALLY good shyt. The finance series gives a great run down on valuations.
EDIT: he embodies what is means to be a cat troll holly shyt
In the weekly investing/ finance series he's like "yeah guys please send over question to Martin@thotpatrol.com " bruh doesn't even say thot he spells it out
Last edited: